See more : UCapital24 S.p.A. (U24.MI) Income Statement Analysis – Financial Results
Complete financial analysis of Huakang Biomedical Holdings Company Limited (8622.HK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Huakang Biomedical Holdings Company Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- MNP Petroleum Corporation (MNAP) Income Statement Analysis – Financial Results
- Yixin Group Limited (2858.HK) Income Statement Analysis – Financial Results
- Franklin Wireless Corp. (FKWL) Income Statement Analysis – Financial Results
- Torrent Pharmaceuticals Limited (TORNTPHARM.NS) Income Statement Analysis – Financial Results
- Fluor Corporation (FLR) Income Statement Analysis – Financial Results
Huakang Biomedical Holdings Company Limited (8622.HK)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.huakangbiomedical.com
About Huakang Biomedical Holdings Company Limited
Huakang Biomedical Holdings Company Limited, an investment holding company, engages in the research, development, manufacture, marketing, and sale of in-vitro diagnostic (IVD) reagents in the People's Republic of China. It offers male and female fertility IVD, parasite antibody detection, and Epstein-Barr virus antibody detection reagents; auxiliary reproductive supplies and equipment; and healthcare products and supplements under the Nutronic brand to customers, as well as through online and offline platforms and channels. The company sells its products directly to hospitals and medical institutions, as well as to distributors. Huakang Biomedical Holdings Company Limited was founded in 1992 and is headquartered in Wan Chai, Hong Kong.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 24.63M | 25.33M | 26.13M | 21.97M | 25.47M | 28.68M | 26.54M | 25.41M | 19.46M |
| Cost of Revenue | 8.54M | 8.42M | 9.67M | 7.25M | 7.58M | 7.10M | 8.01M | 7.79M | 5.09M |
| Gross Profit | 16.09M | 16.91M | 16.46M | 14.72M | 17.89M | 21.58M | 18.53M | 17.62M | 14.37M |
| Gross Profit Ratio | 65.34% | 66.77% | 62.98% | 67.00% | 70.24% | 75.25% | 69.83% | 69.35% | 73.85% |
| Research & Development | 2.55M | 2.48M | 2.44M | 2.25M | 1.76M | 1.47M | 1.37M | 1.21M | 1.64M |
| General & Administrative | 9.87M | 9.80M | 9.35M | 10.19M | 9.68M | 13.58M | 13.31M | 896.00K | 436.00K |
| Selling & Marketing | 8.62M | 8.95M | 8.35M | 7.12M | 6.78M | 4.07M | 2.86M | 2.91M | 2.73M |
| SG&A | 18.49M | 18.75M | 17.70M | 17.32M | 16.46M | 17.65M | 16.17M | 3.81M | 3.17M |
| Other Expenses | -4.95M | 37.00K | 100.00K | 3.00M | -94.00K | -150.00K | 2.00K | 3.00K | -72.00K |
| Operating Expenses | 16.09M | 21.27M | 20.24M | 22.57M | 18.12M | 18.97M | 19.16M | 6.42M | 5.10M |
| Cost & Expenses | 32.02M | 29.69M | 29.91M | 29.82M | 25.70M | 26.07M | 27.16M | 14.21M | 10.19M |
| Interest Income | 404.00K | 402.00K | 179.00K | 185.00K | 174.00K | 84.00K | 143.00K | 159.00K | 1.29M |
| Interest Expense | 53.00K | 55.00K | 102.00K | 74.00K | 72.00K | 1.36M | 54.00K | 123.00K | 1.28M |
| Depreciation & Amortization | 3.18M | 3.14M | 2.95M | 3.19M | 2.76M | 1.69M | 1.42M | 908.00K | 511.00K |
| EBITDA | -2.55M | 188.00K | -852.00K | -8.10M | 3.49M | 4.29M | 1.23M | 12.27M | 10.99M |
| EBITDA Ratio | -10.35% | 0.74% | -3.26% | -25.26% | 12.69% | 14.97% | 4.63% | 48.28% | 56.50% |
| Operating Income | -6.48M | -2.95M | -3.80M | -8.74M | 470.00K | 2.60M | -193.00K | 11.36M | 10.48M |
| Operating Income Ratio | -26.32% | -11.65% | -14.55% | -39.80% | 1.85% | 9.08% | -0.73% | 44.71% | 53.87% |
| Total Other Income/Expenses | 701.00K | 2.08M | 675.00K | -2.75M | 641.00K | -1.39M | -54.00K | -1.26M | -66.00K |
| Income Before Tax | -5.78M | -3.01M | -3.90M | -11.37M | 658.00K | 1.24M | -247.00K | 9.94M | 9.20M |
| Income Before Tax Ratio | -23.48% | -11.87% | -14.94% | -51.77% | 2.58% | 4.33% | -0.93% | 39.13% | 47.30% |
| Income Tax Expense | 0.00 | 68.00K | 317.00K | 255.00K | 942.00K | 1.70M | 1.71M | 1.52M | 1.27M |
| Net Income | -5.78M | -3.08M | -4.22M | -11.63M | -284.00K | -459.00K | -1.95M | 8.43M | 7.93M |
| Net Income Ratio | -23.48% | -12.14% | -16.15% | -52.93% | -1.11% | -1.60% | -7.35% | 33.16% | 40.78% |
| EPS | -0.01 | -0.01 | -0.01 | -0.03 | 0.00 | 0.00 | 0.00 | 0.02 | 0.02 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.03 | 0.00 | 0.00 | 0.00 | 0.02 | 0.02 |
| Weighted Avg Shares Out | 415.96M | 404.64M | 400.00M | 400.00M | 400.00M | 305.21M | 400.00M | 400.00M | 400.00M |
| Weighted Avg Shares Out (Dil) | 415.96M | 404.64M | 400.00M | 400.00M | 400.00M | 305.21M | 400.00M | 400.00M | 400.00M |
Source: https://incomestatements.info
Category: Stock Reports